HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts.

Abstract
Diabetic patients are susceptible to severe inflammatory periodontitis manifesting as swollen gingiva with bleeding, but the underlying mechanism is not well understood. Our purpose was to determine the effect of a high glucose (HG) condition on the interleukin-6/soluble interleukin-6 receptor (IL-6/sIL-6R)-induced activation of signaling and vascular endothelial growth factor (VEGF) expression in human gingival fibroblasts (HGFs). In this study, HGFs were cultured for at least two passages under a normal glucose (NG; 5.5 mM) condition or high glucose (25 mM) condition. Importantly, the HG condition significantly induced expression of gp130 mRNA in HGFs compared with levels in control cells. Consistent with the expression of its mRNA, the HG condition also increased the expression of gp130 protein, and phosphorylation of the tyrosine residue by gp130 was enhanced significantly by IL-6/sIL-6R stimulation. Furthermore, the HG condition enhanced the IL-6/sIL-6R-induced phosphorylation of p44/42 MAPK and led to subsequent activation of CCAAT/enhancer binding protein in nuclei. In contrast, there was no significant difference in phosphorylation of JNK between the HG and NG condition. Interestingly, HGFs increased IL-6/sIL-6R-induced VEGF165 mRNA expression and VEGF165 secretion under the HG condition compared with levels under the NG condition. In contrast, the induction of VEGF165 secretion was partially inhibited by PD98059 (selective p44/42 MAPK inhibitor) under the HG condition. In addition, the VEGF165 secretion was completely inhibited by the combination of PD98059 and SP600125 (JNK inhibitor). Our findings suggest that the HG condition indirectly increases VEGF expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in HGFs. Thus, elevated VEGF secretion in HGFs under the HG condition may play a role in the development of the severe periodontitis observed in diabetic patients.
AuthorsKazuhiro Omori, Koji Naruishi, Fusanori Nishimura, Hisa Yamada-Naruishi, Shogo Takashiba
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 279 Issue 8 Pg. 6643-9 (Feb 20 2004) ISSN: 0021-9258 [Print] United States
PMID14676217 (Publication Type: Journal Article)
Chemical References
  • CCAAT-Enhancer-Binding Proteins
  • Contactins
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Flavonoids
  • Interleukin-6
  • Neural Cell Adhesion Molecules
  • RNA, Messenger
  • Receptors, Interleukin-6
  • Recombinant Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Tyrosine
  • DNA
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Glucose
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
Topics
  • Blotting, Western
  • CCAAT-Enhancer-Binding Proteins
  • Cell Line
  • Cell Nucleus (metabolism)
  • Contactins
  • DNA (chemistry)
  • DNA-Binding Proteins (chemistry)
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Enzyme Inhibitors (pharmacology)
  • Fibroblasts (metabolism)
  • Flavonoids (pharmacology)
  • Gingiva (metabolism)
  • Glucose (pharmacology)
  • Humans
  • Interleukin-6 (metabolism)
  • Mitogen-Activated Protein Kinase 1 (metabolism)
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases (metabolism)
  • Models, Biological
  • Neural Cell Adhesion Molecules
  • Phosphorylation
  • RNA, Messenger (metabolism)
  • Receptors, Interleukin-6 (metabolism)
  • Recombinant Proteins (chemistry)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction
  • Time Factors
  • Tyrosine (chemistry)
  • Vascular Endothelial Growth Factor A (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: